Augmentin vs generic amoxicillin/clavulanate is a comparison between an original brand-name prescription antibiotic and approved generic products containing the same two active ingredients. Branded Augmentin contains amoxicillin and clavulanate potassium, while appropriately approved generic equivalents contain the corresponding active components in the same labeled strength, dosage form and route of administration. The FDA requires generic applicants to satisfy pharmaceutical-equivalence, bioequivalence, labeling and quality standards. The original brand and an approved equivalent generic can differ in appearance, certain inactive ingredients, packaging and commercial supplier without those differences establishing that the brand is clinically superior.
The comparison must be made at the individual product level. Conventional Augmentin tablets include strength pairs such as 250 mg/125 mg, 500 mg/125 mg and 875 mg/125 mg. Chewable tablets and oral suspensions use other strength pairs and concentrations, while Augmentin XR is a distinct extended-release tablet and Augmentin ES-600 is a separately labeled pediatric suspension. FDA approval of a generic conventional tablet does not establish equivalence to XR, ES-600 or a different strength. Orange Book therapeutic-equivalence evaluations should therefore be checked for the specific product rather than inferred from the shared ingredients or Augmentin name.
For someone reviewing a U.S. prescription or pharmacy quotation, the practical distinction is between the prescribed branded product and an appropriately approved generic corresponding to the same formulation. A brand price should be compared with a generic quotation only when the complete strength, dosage form, quantity, location and payment conditions are identified. The pharmacy must also confirm the actual product and applicable substitution requirements. This page focuses on FDA equivalence, pharmacy substitution and brand-versus-generic comparison; the Augmentin brand guide and amoxicillin/clavulanate product guide cover the individual product families.
Augmentin is the proprietary brand name for a combination of amoxicillin and clavulanate potassium. A generic amoxicillin/clavulanate product is an approved pharmaceutical alternative to a corresponding branded presentation when it satisfies the FDA requirements applicable to that reference product. The generic is not a different antibiotic merely because its packaging carries another company name.
For an appropriately approved equivalent generic, the active ingredients, their strengths, dosage form and route of administration correspond to those of the reference product. The generic manufacturer must also demonstrate bioequivalence under applicable FDA standards. These requirements are intended to support the same clinical effect and safety profile under labeled conditions of use.
Some product characteristics can differ. FDA-approved generics may have different colors, shapes, markings, flavors, packaging and certain inactive ingredients. A generic manufacturer may also use a different labeler or distributor. Such differences do not automatically indicate inferior quality or reduced antibacterial activity.
The word generic does not identify a single manufacturer or package. Multiple approved ANDA holders may supply corresponding combination formulations, and pharmacies may dispense products bearing different NDCs. A comparison should therefore distinguish the FDA-approved product from the company named on the dispensed package.
Plain amoxicillin is not a generic version of Augmentin. It lacks clavulanate and has a different active-ingredient composition. Similarly, original Augmentin XR and ES-600 should not be grouped with conventional combination generics without evaluating the specific formulation.
The Augmentin generic manufacturers directory explains company and approval records. This page addresses the meaningful differences between the brand and its appropriately approved equivalents.
| Characteristic | Brand Augmentin | FDA-approved corresponding generic |
|---|---|---|
| Product name | Augmentin proprietary name | Amoxicillin and clavulanate potassium established names |
| Active ingredients | Amoxicillin and clavulanate potassium | Same corresponding active ingredients |
| Strength and dosage form | Specific branded product presentation | Must match the relevant reference product under applicable approval requirements |
| Regulatory application | Approved NDA product | Approved ANDA product |
| Bioequivalence | Reference for applicable generic comparisons | Must satisfy applicable bioequivalence requirements |
| Appearance and inactive ingredients | Brand-specific formulation characteristics | May differ within FDA requirements |
| Pharmacy price | Requires a brand-specific quotation | Requires a product-specific generic quotation |
| Current inventory | Must be confirmed by the pharmacy | Must be confirmed by the pharmacy |
The FDA generally approves generic prescription medicines through an Abbreviated New Drug Application, or ANDA. This pathway relies on the agency's prior finding that the appropriate reference drug is safe and effective, while requiring the generic applicant to demonstrate that its product meets the relevant generic approval standards.
A generic applicant must establish pharmaceutical equivalence to the appropriate reference product. This involves the same active ingredients, corresponding strength, dosage form and route of administration, together with applicable quality standards. For Augmentin-type products, both amoxicillin and clavulanate quantities are essential.
The applicant must also satisfy bioequivalence requirements. Bioequivalence evaluates whether the generic and reference product deliver the active ingredients at sufficiently comparable rates and extents under the applicable testing framework. The specific evidence required can depend on the dosage form and product characteristics.
Generic approval also requires appropriate labeling and compliance with manufacturing quality requirements. FDA-approved generics are subject to the same applicable standards for identity, strength, purity and quality as brand-name medicines. A lower commercial price is not evidence that a generic has passed a less protective safety standard.
An ANDA approval is associated with particular product entries and strengths. It should not be extended automatically to every formulation sold under the broad name amoxicillin/clavulanate. A company approved for conventional tablets has not, by that fact alone, demonstrated approval for extended-release XR or a specialized pediatric suspension.
The FDA Orange Book identifies approved products, application holders and relevant therapeutic-equivalence information. The FDA-approved Augmentin products guide provides the broader approval context, while this section explains what an ANDA means for brand-versus-generic comparison.
| FDA approval concept | What it establishes | What it does not establish |
|---|---|---|
| NDA | Regulatory application for a branded or other new drug product | That every formulation in the brand family is interchangeable. |
| ANDA | Approval of a generic product meeting applicable requirements | That the generic is currently marketed or stocked. |
| Pharmaceutical equivalence | Corresponding active ingredients, strength, dosage form and route | That different formulations or strengths can be exchanged freely. |
| Bioequivalence | Required comparability of drug availability under applicable FDA standards | That appearance and every inactive ingredient must be identical. |
| Therapeutic equivalence | FDA evaluation supporting expected equivalent clinical effect and safety under labeled conditions | Universal equivalence across unrelated product forms. |
| Current Good Manufacturing Practice | Applicable manufacturing quality requirements | That a specific pharmacy currently has the product available. |
The FDA Orange Book provides therapeutic-equivalence evaluations for approved multisource prescription drug products. These evaluations help healthcare professionals and state agencies understand which products the FDA considers therapeutically equivalent. They are specific to the relevant drug product rather than a general declaration that all products containing the same ingredients may replace one another.
The Orange Book distinguishes pharmaceutical equivalence from therapeutic equivalence. Pharmaceutical equivalents contain the same active ingredients in the same amounts and dosage form and use the same route of administration. Therapeutic equivalence additionally involves the applicable bioequivalence and regulatory requirements supporting the expectation of the same clinical effect and safety profile under labeled conditions.
For many multisource prescription products, an A-rated code indicates that FDA considers the products therapeutically equivalent to appropriate pharmaceutically equivalent products. Codes such as AB indicate that the relevant bioequivalence requirements have been met. Numeric suffixes, including AB1 or AB2, distinguish certain equivalence groups and must be matched correctly where they appear.
A B-rated product is not considered therapeutically equivalent to other pharmaceutically equivalent products under the FDA's current evaluation. This classification should not be interpreted as a blanket conclusion that a medicine is unsafe or ineffective; it addresses the specific therapeutic-equivalence determination.
An Orange Book code must be considered alongside the product's active ingredients, strength, dosage form, application and product number. An AB evaluation for a conventional 875 mg/125 mg tablet does not establish equivalence to an extended-release tablet or oral suspension. Approval alone also does not establish a current commercial supply.
FDA's August 2026 final guidance on therapeutic-equivalence evaluations reinforces this product-specific framework. The agency's published guidance and current Orange Book entries should be preferred over a retailer's unsupported description of a product as equivalent.
A pharmacist determines how an applicable FDA evaluation interacts with the prescription and state substitution requirements. Patients should not use an isolated equivalence code as permission to alter a prescribed antibiotic.
Conventional immediate-release Augmentin tablets have FDA-labeled strength pairs of 250 mg/125 mg, 500 mg/125 mg and 875 mg/125 mg. The first amount identifies amoxicillin; the second identifies clavulanic acid. A corresponding generic product must be evaluated using the complete two-component strength and its specific dosage form.
A generic 500 mg/125 mg conventional tablet should not be confused with plain amoxicillin 500 mg. The latter lacks clavulanate and is a different prescription medicine. The same distinction applies to the 875 mg/125 mg combination strength and plain amoxicillin 875 mg.
FDA approval of a generic conventional tablet does not mean that it will have the same color, shape, coating or imprint as original branded Augmentin. These presentation differences can be consistent with generic approval. The actual product should nevertheless be verified through its current labeling and pharmacy identifiers.
Even within the conventional Augmentin family, different strength pairs are not freely interchangeable. For example, two 250 mg/125 mg conventional tablets contain more clavulanic acid than one 500 mg/125 mg tablet. FDA labeling warns against treating these as equivalent substitutions.
The cleanest commercial comparison uses the same conventional strength and quantity for the original brand and a verified generic. Different package counts or strength pairs can make an advertised price difference misleading. The pharmacy must confirm the product it is actually able to dispense.
Product-specific details are available in the Augmentin tablets guide, 500/125 mg guide and 875/125 mg guide. This section concentrates on brand-versus-generic identity rather than repeating the complete tablet catalog.
The brand-versus-generic comparison also applies to approved chewable tablets and oral suspensions, but these products must be evaluated within their own dosage-form categories. An FDA-approved generic conventional tablet is not automatically a generic equivalent of a branded chewable tablet or liquid.
Standard Augmentin chewables are labeled in strength pairs of 125 mg/31.25 mg, 200 mg/28.5 mg, 250 mg/62.5 mg and 400 mg/57 mg per tablet. Standard oral suspensions use the corresponding two-component quantities per 5 mL after reconstitution. These should not be confused with conventional tablets that contain different proportions of the two ingredients.
An approved generic chewable may differ from the brand in color, flavor, shape or certain inactive ingredients within applicable FDA requirements. Similarly, a generic suspension may have product-specific flavoring agents, excipients, bottle configurations and labeler information. These differences can matter for identification and individual ingredient concerns without establishing automatic clinical inferiority.
Liquid product quotations must identify the prepared concentration and final volume. A generic 400 mg/57 mg per 5 mL suspension is not the same commercial listing as a generic 250 mg/62.5 mg per 5 mL suspension. Matching the amoxicillin number or bottle size alone is insufficient.
Augmentin ES-600 is a separate 600 mg/42.9 mg per 5 mL pediatric formulation with distinct FDA-labeled restrictions. A generic standard suspension cannot be assumed equivalent to ES-600 simply because both are powders for oral suspension.
The chewable product guide, standard suspension guide and ES-600 guide own the detailed product descriptions. This comparison focuses on the matching requirements for a branded product and its approved generic counterpart.
| Product category | Brand identification | Generic-equivalence boundary |
|---|---|---|
| Conventional tablets | 250/125, 500/125 or 875/125 mg | Compare the corresponding immediate-release strength and product-specific FDA evaluation. |
| Chewable tablets | 125/31.25, 200/28.5, 250/62.5 or 400/57 mg per tablet | Use chewable-specific strength and approval records. |
| Standard oral suspension | 125/31.25, 200/28.5, 250/62.5 or 400/57 mg per 5 mL | Use matching concentration and dosage form; verify dispensed volume. |
| Augmentin XR | 1,000/62.5 mg extended-release tablet | Do not infer equivalence from conventional immediate-release products. |
| Augmentin ES-600 | 600/42.9 mg per 5 mL pediatric suspension | Do not infer equivalence from standard suspension generics. |
Augmentin XR and Augmentin ES-600 are distinct members of the broader amoxicillin/clavulanate product family. Their formulation characteristics prevent generic-equivalence conclusions from being transferred automatically from ordinary Augmentin tablets and suspensions.
Augmentin XR contains 1,000 mg of amoxicillin and 62.5 mg of clavulanic acid per extended-release tablet. Its bilayer release design differs from conventional immediate-release tablets. A combination of regular tablets that produces a similar total amount of amoxicillin does not reproduce the XR clavulanate amount or release profile.
An extended-release generic must be verified against the appropriate extended-release reference product and FDA application records. The presence of a historical extended-release generic approval does not by itself establish present marketing or stock. The FDA's regulatory actions associated with XR relaunch efforts likewise should not be treated as proof of retail availability.
Augmentin ES-600 contains 600 mg of amoxicillin and 42.9 mg of clavulanic acid per 5 mL after reconstitution. It has a different ratio from standard suspension products and specific FDA labeling. A standard 400 mg/57 mg per 5 mL suspension should not be described as an ES-600 generic substitute.
If a pharmacy cannot obtain an intended XR or ES-600 product, any proposed alternative must be reviewed under the prescription, applicable product approvals and professional requirements. Commercial convenience or price differences do not override formulation-specific restrictions.
The Augmentin XR guide and ES-600 vs regular Augmentin comparison address those special formulations in greater detail.
An FDA-approved generic amoxicillin/clavulanate product does not need to look identical to the original Augmentin brand. Shape, color, markings, coating, packaging and certain inactive ingredients can differ. These differences are consistent with the FDA's generic-drug framework when the product meets the applicable approval requirements.
Inactive ingredients are not always irrelevant to an individual patient. A particular coloring agent, flavor, sweetener or other excipient may matter when there is a documented allergy, intolerance or condition-specific restriction. However, such concerns should be assessed using the actual product label rather than assumptions about all generic medicines.
Chewable tablets and oral suspensions can have more noticeable differences in taste and flavoring than conventional tablets. Their specific excipients should be checked against the manufacturer's labeling. A pleasant flavor or a different tablet appearance does not establish therapeutic equivalence or clinical superiority.
Generic products may also be associated with several company roles. The ANDA holder is the approved application holder, whereas the labeler, distributor or repackager shown on the package can be different. The FDA Orange Book identifies applicants; DailyMed can add product-specific labeler and package information.
A change in generic manufacturer should not automatically be interpreted as a medication error. Nevertheless, patients should confirm the medicine's active ingredients, strength and dosage form, especially when the package looks different from a previous fill.
The Augmentin product authenticity guide addresses identification and packaging checks. This section explains why lawful brand and generic products may appear different.
Original brand Augmentin and approved generic amoxicillin/clavulanate can have different pharmacy pricing arrangements. Generic competition may influence prices, but no universal discount percentage or fixed price difference can be established without current comparable quotations.
A meaningful comparison begins with the same dosage form and strength pair. For example, a brand 875 mg/125 mg conventional tablet price should be compared with a corresponding approved generic 875 mg/125 mg conventional tablet quote, not with plain amoxicillin, a chewable tablet or an XR product.
Prescription quantity must also match. A quotation for 14 tablets cannot be directly ranked against a different quantity without identifying the difference. For suspension, the full concentration and prepared liquid volume are essential. Brand and generic bottle configurations may differ, which can further affect commercial comparisons.
The payment basis matters because ordinary cash prices, discount-card estimates and insurance cost sharing are not the same. A coupon service may display Augmentin as the search heading while quoting generic amoxicillin/clavulanate. Such an amount should be classified as a generic price rather than presented as a branded offer.
A lower quotation does not establish that the product is currently stocked, clinically appropriate or permitted for substitution under a particular prescription. The dispensing pharmacy must verify the actual product and transaction conditions.
The brand Augmentin price guide owns branded cost factors, while generic Augmentin pricing covers generic quotations. This comparison explains the conditions required for a fair brand-versus-generic price evaluation without reproducing changing commercial offers.
| Comparison field | Correct matching rule | Misleading comparison |
|---|---|---|
| Active ingredients | Amoxicillin plus clavulanate in both products | Brand Augmentin versus plain amoxicillin. |
| Strength | Both active-component quantities match | 500/125 mg brand versus another strength. |
| Dosage form | Same conventional tablet, chewable or suspension category | Immediate-release brand tablet versus XR or liquid. |
| Quantity | Same tablet count or matching prepared liquid volume | Different quantities without disclosure. |
| Product status | Original branded Augmentin versus identified approved generic | Generic coupon presented as a brand price. |
| Payment terms | Comparable cash, discount or insurance conditions | Coupon amount compared directly with an insurance copay. |
| Pharmacy and date | Identified pharmacy, region and comparable observation date | Historical reference presented as a current nationwide price. |
A pharmacist may be permitted to dispense an appropriately approved generic equivalent in place of a prescribed brand-name product when the prescription and applicable state substitution requirements allow it. The decision must involve the corresponding drug product rather than merely another medicine containing one shared ingredient.
The FDA Orange Book helps establish product-specific therapeutic-equivalence relationships. The pharmacist must also consider the prescribed strength, dosage form, route, quantity and any applicable brand-dispensing instruction. State laws and pharmacy requirements can affect whether and how substitution occurs.
A generic conventional 500 mg/125 mg tablet may be relevant to a prescription for the corresponding branded conventional tablet when the applicable approval and substitution requirements are satisfied. This does not imply that a different strength, chewable or suspension can be substituted without further evaluation.
The distinction is especially important for Augmentin XR and ES-600. The FDA labeling identifies non-substitution restrictions involving these separate formulations. A pharmacy should not replace a prescribed XR product with conventional immediate-release tablets merely to reduce cost or fill an order more quickly.
Patients should not independently switch between original brand and generic products, combine tablet strengths or alter oral suspension concentrations. If the supplied medicine differs from the expected brand or package, the pharmacist can explain the generic relationship and confirm whether the product matches the prescription.
A valid prescription remains necessary for both the original brand and generic products. Commercial availability, an online discount or an insurance formulary listing does not establish that a specific substitution is lawful or clinically appropriate.
The Augmentin online pharmacy guide addresses general dispensing service verification. This section focuses on the product-specific requirements for substituting brand and generic medicines.
A practical Augmentin brand-versus-generic comparison should begin with a valid prescription and the exact product requested. The first step is to confirm that both products contain amoxicillin and clavulanate potassium, not plain amoxicillin alone.
Next, identify the complete strength pair and dosage form. For conventional tablets, both ingredient quantities must match. For oral suspensions, the concentration must be expressed as the amounts of both ingredients per 5 mL, together with the prescribed prepared volume. Chewables, XR and ES-600 require their own product-specific verification.
If a generic is proposed, the pharmacy can identify the actual approved product and relevant FDA approval or therapeutic-equivalence information. The labeler and NDC may help reconcile different package names, but those identifiers alone do not establish therapeutic equivalence or stock.
The pharmacist should also confirm that generic substitution is permitted under the prescription and applicable requirements. Any clinically relevant concern about ingredients, dosage form or product availability should be addressed professionally instead of resolved by self-selection.
After product identity is verified, brand and generic costs may be compared using the same quantity, pharmacy location, payment method and quote date. Current availability remains a separate question because approval records do not function as live inventory systems.
Finally, the patient should understand that both products remain prescription antibiotics. They should not be used for viral illnesses, shared with another person or saved for a future infection. The role of the comparison is to clarify approved equivalent products and their commercial differences, not to recommend antibiotic treatment.
Augmentin is the original brand-name combination of amoxicillin and clavulanate potassium. FDA-approved corresponding generics contain the same active ingredients in the matching strength and dosage form and must meet applicable bioequivalence and quality requirements. Appearance, certain inactive ingredients, package identifiers and manufacturer names may differ.
An FDA-approved therapeutically equivalent generic is expected to provide the same clinical effect and safety profile as its corresponding reference product when used under labeled conditions. This conclusion applies to the specific approved equivalent product, not to every amoxicillin/clavulanate formulation.
An approved corresponding generic contains amoxicillin and clavulanate potassium in the required matching active-component strengths. Its inactive ingredients may differ within FDA requirements. Plain amoxicillin is not a generic equivalent of Augmentin because it lacks clavulanate.
FDA-approved generic amoxicillin/clavulanate products exist. Approval is associated with specific ANDAs, strengths and dosage forms. A product should be verified through the appropriate FDA approval record rather than assuming that every similarly named listing is approved.
ANDA means Abbreviated New Drug Application. It is the FDA approval pathway generally used for generic products that meet applicable requirements for pharmaceutical equivalence, bioequivalence, labeling and manufacturing quality.
An AB rating generally indicates that a multisource prescription drug product has met the relevant bioequivalence requirements and is considered therapeutically equivalent to appropriate pharmaceutically equivalent products in its Orange Book group. The code must be interpreted with the exact drug, strength and dosage form.
No. Orange Book therapeutic-equivalence evaluations are product-specific. A code associated with a conventional tablet should not be extended automatically to a chewable, oral suspension, XR tablet or ES-600 product.
FDA-approved generics may differ from the brand in color, shape, markings, packaging and certain inactive ingredients. These differences are allowed within applicable approval standards and do not, by themselves, indicate inferior quality or reduced effectiveness.
Yes. Approved products may have different fillers, coatings, coloring agents, flavorings or other excipients. The actual product label should be checked when a specific ingredient matters to the patient.
No universal price difference can be guaranteed. Generic competition may affect pricing, but the actual cost depends on the product, strength, quantity, pharmacy, location and payment terms. A current like-for-like quotation is needed for a meaningful comparison.
An appropriately approved generic equivalent may be dispensed when the prescription, applicable therapeutic-equivalence requirements and state pharmacy laws permit. Matching active ingredients alone does not authorize substitution between different strengths or dosage forms.
No. Plain amoxicillin 500 mg contains amoxicillin alone, while generic amoxicillin/clavulanate 500 mg/125 mg contains amoxicillin plus clavulanate. They are different prescription medicines and are not generic equivalents of one another.
Yes. FDA-approved generic amoxicillin/clavulanate conventional tablets include the 875 mg/125 mg strength. The approved applicant, actual product and current pharmacy availability should be verified separately.
FDA-approved generic suspensions may be therapeutically equivalent to their corresponding reference products when the specific formulation meets applicable approval and equivalence requirements. Concentration, dosage form and product identity must be matched; not every combination liquid is interchangeable.
No. Augmentin XR is a distinct extended-release product with different release characteristics and a specific strength pair. Conventional immediate-release generic tablets are not automatically interchangeable with XR.
No. Augmentin ES-600 is a separate pediatric suspension containing 600 mg/42.9 mg per 5 mL with distinct FDA labeling and substitution restrictions. A standard generic suspension should not be assumed equivalent.
Not necessarily. Commercial and Medicare drug plans may distinguish original brand Augmentin from generic amoxicillin/clavulanate through formulary placement, cost sharing or coverage restrictions. The actual plan and prescribed product must be checked.
No. Both branded Augmentin and generic amoxicillin/clavulanate are prescription-only antibacterial medicines in the United States. Lawful dispensing requires a valid prescription and compliance with applicable pharmacy requirements.